Both authors equally share credit. ‡ Both authors will share credit for senior authorship.
Introduction
Dendritic cells (DCs) mediate key events in priming, shaping and sustaining tumor immunity [1, 2] . Consequently, many investigators have tested ex vivo differentiated DC to formulate vaccines against tumor antigens [3] . The best results to date have been reported with DC loaded with tumor neoantigens [4] , DC transfected with clinical grade mRNAs to transfer antigens and enhance their performance [5] , antigen-loaded DCs with autologous tumor lysates [6, 7] and with myeloid DC directly isolated from peripheral blood [3] .
Mimicking an acute viral infection inside malignant tissue is becoming a paradigm to maximize tumor immunity [8] [9] [10] [11] . In this regard, poly-I: C is well known to mimic double stranded RNA (dsRNA) as a TLR-3 agonist in endosomes and as a RIG-I or MDA-5 agonist if reaching the cytosol [12] . These functions confer poly I: C a strong adjuvant activity when formulated in vaccines to elicit robust cytotoxic T lymphocytes [13] . Hiltonol (Poly-ICLC) is a GMP-grade form of poly I: C stabilized by poly L-lysine and formulated for injection [14] . Safety is excellent and it has been catalogued as an endogenous type I interferon inducer. It shows antitumor activity in mice [11, 15, 16] and has been tested in clinical trials [17] [18] [19] . Subcutaneous injection in a cohort of healthy volunteers induced transient local dermatitis and a rapid and prominent upregulation of a type I IFN-related transcriptional signature in peripheral blood mononuclear cells (PBMCs) [17] . Moreover, Hiltonol has been delivered intratumorally in advanced cancer patients [18, 19] and intramuscularly in advanced glioblastoma patients with non-surgically amenable disease in combination with peptide-pulsed DC vaccines [20] . Evidence of clinical activity was reported in some of the cases, along with an excellent safety profile. 
Patients and methods

Results
Clinical trial rationale, description and results
Hiltonol (poly-ICLC) intratumoral injection showed signs of therapeutic activity in BALB/c mice against 10-day established CT26-derived subcutaneous tumors, in particular when combined with a vaccine approach based on bone marrow-derived GM-CSF DCs loaded with tumor lysate and matured in the presence of Hiltonol, IFN-a and TNF-a (supplementary Figure S1 , available at Annals of Oncology online).
To implement a similar strategy in humans, DC vaccines were prepared from autologous immunomagnetically isolated CD14 þ monocytes in 7-day differentiation cultures with GM-CSF and IL-4, loaded with freeze/thaw tumor lysates from a needle tumor biopsy, and matured for 24 h with Hiltonol, IFN-a and TNF-a. Identity, purity and maturation of the DC products were as shown in supplementary Figure S2 , available at Annals of Oncology online and consistent with our previously reported trials of similar cell therapy products [21, 22] . There were no consistent differences in the phenotype and maturation status of DC in patients who achieved stable disease (SD) as compared with those progressing to treatment. In matured DC cultures, a tendency to produce larger amounts of IL-6 and IL-8 was noted in those patients who eventually progressed (supplementary Figure  S2 , available at Annals of Oncology online).
Study treatment is presented in Figure 1A and consisted of cyclophosphamide (600 mg/m 2 ) on day -7 of each cycle to reduce Treg cells and myeloid suppressor cells [21] ; four daily intradermal DC vaccinations in alternating upper thigh regions from day 1 to 4 of each cycle; and image-guided intratumoral injection of 0.25 mg of Hiltonol in 0.5 ml of saline per dose into an accessible lesion on days 8 and 10 of each cycle.
Two patient cohorts were included (cohort-1 and cohort-2) and their clinical features are summarized in Table 1 . Ten patients were recruited in cohort-1 and nine completed treatment (Table 1) . Patient 8 signed consent, but was a screening failure due to laboratory values that did not meet inclusion criteria. Treatment was well tolerated and only grades 1-2 side effects attributable to treatment were observed. Four patients experienced SD by RECIST1.1 in the first tumor evaluation carried out 6-7 weeks after treatment onset and five patients progressed. Supplementary Table S1 , available at Annals of Oncology online differentially shows CT-SCAN evaluation of directly treated and distant tumor lesions without evidence for distinct outcomes. Subsequent lines of treatment and duration of treatment until a new line of therapy are included in supplementary Table 2 , available at Annals of Oncology online.
One of the patients (patient 6) with metastatic head and neck cancer continues to show SD at month 51, although this patient was treated subsequently in month 34 with a recombinant IL-2 agent in a different clinical trial (NCT02627274) despite not having ever progressed.
After treatment of the first 10 planned patients (cohort-1), the trial protocol was amended to recruit six additional patients who received fractionated stereotactic ablative radiotherapy (SABR) to the lesion injected with Hiltonol and other local or regional lesions (cohort-2). Radiotherapy consisted of 24 Gy in three fractions given every other day from day 7 to 11 ( Figure 1A ).
Among patients treated with SABR only grades 1-2 adverse events were observed (Table 1 ). In spite of being heavily pretreated patients, five experienced disease stabilization by RECIST1.1 criteria as their best response. All patients were examined per-protocol by 18 F-FDG PET-CT before treatment and 6-7 weeks after immunotherapy onset. Table 1 shows the summatory change in standard up-take value (SUV) in target lesions that excluded those which received irradiation in cohort-2. In five cases there was reduction of SUV (Table 1) .
Patient 11, one of the patients presenting SD, was a 68-year-old black male diagnosed with advanced castration-resistant prostate carcinoma presenting a prostatic mass, lung, mediastinal and inguinal lymph-node metastases and bone marrow infiltration. Hiltonol was injected into metastatic inguinal lymph nodes and SABR was administered to the prostatic tumor and the inguinal lymph nodes ( Figure 1B) . PET imaging carried out 3 months following treatment showed evidence of response in the thoracic and retroperitoneal metastatic lesions, which became cystic ( Figure 1C and D) . Moreover, a drastic reduction in the size of mediastinal and retroperitoneal lesions was observed in a CT-SCAN carried out 6 months following treatment onset ( Figure  1E ). A PSA serum concentration reduction followed the radiological pattern (from 120.7 to 97.5 ng/ml). Despite this evidence of activity, resulting in a mixed response, the patient did not achieve a partial response according to RECIST1.1 criteria and radiologically progressed 12 months later with corresponding increases in serum PSA. This patient consented to a post-treatment biopsy being carried out immediately before the second intratumoral injection of Hiltonol of the second treatment cycle (day þ30). 
Exploratory studies in peripheral blood on immune parameters related to outcome
To assess signs of increased immune activity, we studied expression in PBMC of 25 relevant immune genes, based on previous experience with Hiltonol administration [17] and DC vaccination [21, 23] . Supplementary Figure S3 , available at Annals of Oncology online represents the relative changes in transcript expression comparing each patient's baseline PBMC with that obtained on day 14 (color code red indicates patients receiving SABR). As can be seen, transcripts for IFNb and IFNa increased in the majority of the patients. Of note, mRNA encoding the chemokines CXCL9 and CXCL10 increased in a fraction of patients experiencing SD. Importantly, no increases in T-cell activation markers, including PD1 and CD137 were found at least at this time point in peripheral blood, while quite surprisingly IFNc transcripts decreased in all patients. However, a multicolor flow cytometry panel on these PBMC samples assessing proportions of T, Treg, NK, B and myeloid cells did not detect noticeable changes or any evidence for variation in T-cell activation markers (data not shown).
The serum concentrations of a panel of 16 cytokines were sequentially studied at baseline, on day 4 and on day 24. In addition, to monitor for vascular inflammation and T-cell activation, serum concentrations of soluble forms of ICAM-1, VCAM and CD25 were monitored. Results in Figure 3 are presented as percentage of change over each patient's baseline value. Interestingly, IL-12 and IL-1b increased in most patients, but were indistinguishable between SD and PD patients on day 4. However, on day 24 the concentration elevations of IL-12 and IL1b were significantly higher in those patients experiencing SD as compared with those progressing at this late time-point. Of note, IFNa was not detectable in serum by ELISA in any of these samples. Interestingly, IL-8 decreased or remained unchanged in SD patients on day 24 while it increased in patients presenting progressive disease. A similar tendency was found for sICAM-1.
Furthermore, patient 6 who remains a long-term non-progressor behaved as an outlier in terms of marked increases in IL-12, IL-1b and IL-10 in serum as well as in PBMC increases of CXCL9, CXCL10, PD-1 and PD-L1 transcripts (supplementary Figure S3 , available at Annals of Oncology online and Figure 3 where this patient is marked with a blue star). Moreover, we carried out IFNc-ELISPOT assays co-culturing PBMC with mature DC loaded with autologous tumor lysate, as those used for treatment. Increased T-cell reactivity was found on day þ42 samples and TCRb sequencing showed a discrete increase of some clones ( Figure 4A ).
Patient 11, who experienced the mixed response, was not an outlier for any of the parameters assessed with the exception of IL-6 serum concentration elevations that were markedly high in this case. These patients' values are specified with stars in supplementary Figure S3 , available at Annals of Oncology online and Figure 3 . In terms of tumor-lysate specific IFNc-ELISPOTs, PBMC showed clear pretreatment reactivity to autologous tumor lysate that was stable or marginally decreased on day þ42, while TCRb sequencing indicated enrichment of some clones ( Figure 4B ). Observations in peripheral blood do not accurately estimate more relevant changes in the tumor microenvironment but at least are indicative of overall immune-associated reactivity in this series of patients.
Discussion
Synergistic cancer Immunotherapy combinations [24] may include local interventions to transform a tumor lesion into an immunogenic vaccine [9] . In this pilot clinical trial we have tested two local interventions, namely Hiltonol intratumoral injections and radiotherapy, in combination with a reportedly safe and bioactive DC vaccine in an intensive regimen [21, 22] .
Efficacious local interventions in combination immunotherapy have been clinically pioneered by intratumoral recombinant herpes virus (T-VEC) þ pembrolizumab, resulting in excellent efficacy in a phase I clinical trial for melanoma patients [25] . Intratumor injections of other microbial-denoting agents are also under active clinical research in combination regimens, including LPS analogues (NCT02501473), other dsRNA analogues [25] , TLR-7 agonists (NCT03276832), TLR-8 agonists [26, 27] , TLR-9 agonists [28] and STING agonists (NCT03172936). Arguably the most promising of such combinations are those that include PD-1/PD-L1 blockade.
We observed five disease stabilizations among six previously progressing and heavily pretreated patients who were treated in the radiotherapy cohort, suggesting that this radioimmunotherapy combination is beneficial to some extent. Some degree of benefit had been previously reported in lymphoma patients with a scheme based on intratumoral injection of TLR-9 agonists and low dose radiotherapy [28] . The proimmune effects of radiotherapy have been extensively reported in mouse models [29, 30] and observed in clinical trials [31, 32] . The mechanisms behind of these phenomena involve immunogenic cell death and proinflammation. We selected our SABR doses in accordance with previously reported experience [33] .
We were able to show increases in IFNa/b mRNA related to intratumor Hiltonol administration [17] and increases in circulating IL-12 and IL1b related to DC administration and perhaps produced at least in part by the injected DC themselves. Associations with outcome, albeit promising, remain speculative. ELISPOT reactivity in durable SD patients is indicative of T-cell priming against tumor antigens in durable SD patients. Interestingly IL-8 levels decreased in SD in comparison to PD patients possibly because IL-8 is a surrogate biomarker of tumor burden [21] .
Conclusion
In conclusion, local and systemic immunotherapy interventions including cancer vaccines could be combined. Refinements in the formulation of the vaccines to focus on tumor neoantigens and the combined instigation of radiotherapy þ intratumoral viralmimicking agents are to be considered in our quest to improve immunotherapeutic results. ELISPOT tumor reactivity and TCRb sequencing of peripheral blood lymphocytes in durable SD patients. Thawed PBMC samples from patient 6 (A) and 11 (B), that had been taken pre-treatment and on day þ42, were co-incubated 36h with mature autologous DC with or without loading autologous tumor lysates. Mean ELISPOT numbers per 10 6 cells are shown 6SD of triplicate wells. Positive controls were SAB superantigen (A) and PMAþionomycin (B). Genomic DNA from the same thawed PBMC samples were quantitatively TCRb-sequenced by ADAPTIVE to assess T-cell clonality comparing pretreatment samples and samples on day þ42. Results for patient 6 (A right) and patient 11 (B right) show the evolution of the different clones. Clones showing increase in frequency are marked with color and followed with the corresponding CDR3 sequence provided.
